GlassScriptPhysician profile
Howard Silk
NPI 1912944828
$4,165.31
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $1,238 · 2021: $824 · 2022: $1,003 · 2023: $63.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $512.72 | 2020-2022 | |
| Csl Behring | $418.61 | 2019-2023 | Haegarda |
| Astrazeneca Pharmaceuticals LP | $380.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $355.64 | 2019-2022 | |
| Pfizer INC. | $355.34 | 2019-2023 | |
| Kaleo, INC. | $276.82 | 2019-2022 | |
| Octapharma USA, INC. | $220.86 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $185.03 | 2019-2022 | |
| Genzyme Corporation | $166.38 | 2020-2022 | |
| Grifols USA, LLC | $158.02 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $157.78 | 2021-2022 | |
| Abbvie INC. | $125.33 | 2021-2023 | Rinvoq |
| Optinose US, INC. | $117.42 | 2019-2022 | |
| Covis Pharma Gmbh | $109.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $86.59 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $81.45 | 2020-2022 | |
| Shire North American Group INC | $76.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.51 | 2020-2021 | |
| Horizon Therapeutics Plc | $60.50 | 2019-2020 | |
| Genentech USA, INC. | $47.85 | 2019 | |
| Alk-Abello, INC | $38.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $34.44 | 2021-2022 | |
| Tersera Therapeutics LLC | $28.21 | 2021 | |
| Adma Biomanufacturing LLC | $23.14 | 2021 | |
| Hikma Pharmaceuticals USA | $19.65 | 2022 | |
| Circassia INC. | $19.27 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.67 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $16.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Silk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.